IP Library Granted Patent US 11,486,802
Granted Patent B2
US 11,486,802 · App. 16/123,056 · Granted Nov 1, 2022

Methods and devices for high throughput purification

Inventors: Joseph D'Silva (Hillsboro, OR); Robert H. Austin (Princeton, NJ); Curt Civin (Baltimore, MD); James C. Sturm (Princeton, NJ)
Assignees: UNIVERSITY OF MARYLAND, BALTIMORE; THE TRUSTEES OF PRINCETON UNIVERSITY
G01N1/34A61K35/14A61K35/28B01L3/502753B01L3/502761G01N15/1404G01N33/5094B01L2200/0652B01L2300/0816B01L2300/0864B01L2300/0867B01L2300/1894B01L2400/086G01N2015/008G01N2015/1006G01N2015/1493G01N2333/70596
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,486,802
App. No.
16/123,056
Granted
Nov 1, 2022
Kind
B2
Abstract

Described herein are devices and methods for high throughput purification of particles. In some cases, methods and devices described herein can be used to remove erythrocytes and purify leukocytes and raise the quality of umbilical cord blood and other transplant grafts, thereby significantly improving patient outcomes.

Claims (27)

1. A method for separating leukocytes in a sample comprising said leukocytes, said method comprising flowing the sample through a microfluidic device wherein:

a) the microfluidic device comprises:

i) a microfluidic channel having at least one inlet and a plurality of outlets; and

ii) an array of obstacles arranged in rows and columns within the microfluidic channel, wherein:

aa) the array of obstacles is configured to differentially separate cells based on size by deflecting cells of at least a predetermined size toward a first outlet while allowing cells of less than the predetermined size to pass to a second outlet;

bb) the adjacent surfaces of two obstacles in a column define a gap with a size of less than 45 micrometers;

b) the sample has not been diluted more than four-fold prior to entering the microfluidic channel; and

c) greater than 100 mL of sample can be processed in 30 minutes.

2. The method of claim 1 , wherein the sample comprising leukocytes is blood or a depleted blood product.

3. The method of claim 1 , wherein platelets are removed from the sample before it is flowed through the microfluidic device.

4. The method of claim 1 , wherein the microfluidic device is run at a flow rate of at least 5 ml per minute and wherein the obstacles are quadrilaterals.

5. The method of claim 1 , wherein the microfluidic device is run at a flow rate of at least 10 ml per minute.

6. The method of claim 1 , wherein the device does not exhibit significant clogging during the processing of sample.

7. The method of claim 1 , wherein 100 ml of whole blood can be processed without significant clogging.

8. The method of claim 1 , wherein the obstacles are rectangular.

9. The method of claim 1 , wherein the blood sample has been diluted two-fold and is flowed through the microfluidic channel at a rate of at least 6 ml/minute.

10. The method of claim 1 , wherein the size of the gap width is 8-44 micrometers.

11. The method of claim 1 , wherein the sample is an undiluted blood sample.

12. The method of claim 1 , wherein the sample is a blood sample that has been diluted up to three fold.

13. The method of claim 1 , wherein the obstacles are quadrilaterals and a side length of the obstacles does not exceed 350 micrometers.

14. The method of claim 1 , wherein the obstacles are quadrilaterals and a side length of the obstacles does not exceed 200 micrometers.

15. The method of claim 1 , wherein the device comprises at least two inlets.

16. The method of claim 1 , wherein buffer is flowed through at least a second inlet.

17. The method of claim 1 , wherein obstacles in adjacent columns are offset from one another by a tilt angle less than 1/20 radians.

18. The method of claim 1 , wherein the sample further comprises erythrocytes.

19. The method of claim 2 , wherein the depleted blood product is an erythrocyte-depleted blood product.

20. The method of claim 2 , wherein the depleted blood product is an platelet-depleted blood product.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2020
From: D'SILVA, JOSEPH; AUSTIN, ROBERT H.; STURM, JAMES C.
To: THE TRUSTEES OF PRINCETON UNIVERSITY
Reel/Frame 053334/0683 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2018
From: CIVIN, CURT I
To: UNIVERSITY OF MARYLAND, BALTIMORE
Reel/Frame 046955/0904 →
Continuity (4)
Continuation 14774260
Provisional Application 61939044 · Feb 12, 2014
Provisional Application 61799835 · Mar 15, 2013
Related Publication 20190137369A1 · May 9, 2019